Table 5 Responses of uLMS147 Patient Derived Xenograft to PARPi and standard therapy in vivo
From: Targeting homologous recombination deficiency in uterine leiomyosarcoma
| Â | Test Statistica | P-value |
|---|---|---|
Vehicle vs caelyx 1.5Â mg/kg | 11.61 | 0.0007 |
Vehicle vs olaparib (6d) 150Â mg/kg (3WKS) | 0.17 | 0.7 |
Vehicle vs olaparib 150Â mg/kg (6WKS) | 0.017 | 0.9 |
Vehicle vs cisplatin 4Â mg/kg | 1.46 | 0.2 |